Pancreatic Cancer Research

ResearcherThe University of Texas Southwestern Medical CenterActive in the last 2 years

Thomas Martin Wilkie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9357-637X; OpenAlex author ID A5003982761. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 8

  1. Pancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the PRECEDE Consortium. Co-author DOI 10.1002/ijc.70592↗
  2. Early cellular plasticity promotes progression and dissemination in pancreatic adenocarcinoma. Last author DOI 10.1007/s10555-026-10326-1↗
  3. Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ijms25126619↗
  4. Gα15 in early onset of pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41598-021-94150-3↗
  5. AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0860↗
  6. Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. Last author DOI 10.1038/s41598-020-77373-8↗
  7. Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA): Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth. Last author DOI 10.1016/j.ajpath.2017.11.014↗
  8. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. Last author DOI 10.1242/dmm.020933↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giulio Innamorati · 4 shared papers, 2021–2026 · strength 0.89
  2. Giorgio Malpeli · 2 shared papers, 2021–2026 · strength 0.48
  3. Roberto Salvia · 2 shared papers, 2021–2026 · strength 0.48
  4. Rolf A. Brekken · 4 shared papers, 2015–2024 · strength 0.43
  5. Yalda Zolghadri · 4 shared papers, 2015–2024 · strength 0.40
  6. Huocong Huang · 3 shared papers, 2020–2024 · strength 0.39
  7. Havish Sairaju Kantheti · 2 shared papers, 2020–2024 · strength 0.26
  8. Christine Worthington · 1 shared paper, 2026 · strength 0.24
  9. Doron Yablecovitch · 1 shared paper, 2026 · strength 0.24
  10. Ido Laish · 1 shared paper, 2026 · strength 0.24
  11. Diane M. Simeone · 1 shared paper, 2026 · strength 0.24
  12. Randall E. Brand · 1 shared paper, 2026 · strength 0.24
  13. George Zogopoulos · 1 shared paper, 2026 · strength 0.24
  14. Jennifer B. Permuth · 1 shared paper, 2026 · strength 0.24
  15. Julie Earl · 1 shared paper, 2026 · strength 0.24
  16. Phil A. Hart · 1 shared paper, 2026 · strength 0.24
  17. Ozhan Ocal · 3 shared papers, 2015–2020 · strength 0.23
  18. Somayeh Layeghi‐Ghalehsoukhteh · 2 shared papers, 2018–2020 · strength 0.19
  19. Wenting Du · 1 shared paper, 2021 · strength 0.12
  20. Muhammad Shaalan Beg · 1 shared paper, 2021 · strength 0.12
  21. Ana Clara P. Azevedo‐Pouly · 1 shared paper, 2020 · strength 0.10
  22. Giuseppe Malleo · 1 shared paper, 2021 · strength 0.09
  23. Rita Teresa Lawlor · 1 shared paper, 2021 · strength 0.09
  24. Claudio Bassi · 1 shared paper, 2021 · strength 0.09
  25. Salvatore Paiella · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.